Endoglycosidase H Inhibitors

Swainsonine inhibits Endoglycosidase H by mimicking the structure of the substrates that Endoglycosidase H acts on, thereby competitively inhibiting the enzyme's active site. This results in the functional inhibition of the enzyme's ability to cleave N-linked oligosaccharides from glycoproteins.

Castanospermine acts as an inhibitor of Endoglycosidase H by occupying the active site due to its structural similarity to the enzyme's natural substrates, which prevents the enzyme from engaging with its actual substrates and performing the cleavage of N-linked glycans.

Deoxynojirimycin inhibits Endoglycosidase H by binding to the active site of the enzyme. This competitive inhibition prevents the enzyme from hydrolyzing the glycosidic linkages of its natural substrates, thus blocking its glycan-cleaving function.

Deoxymannojirimycin inhibits Endoglycosidase H by imitating the structure of mannose, a common component of N-glycans. This imitative binding blocks the active site of the enzyme, which prevents the cleavage of glycans from glycoproteins.

Kifunensine inhibits Endoglycosidase H by binding to and inhibiting mannosidase I, which is crucial for the processing of N-glycans that Endoglycosidase H would typically cleave. This upstream inhibition reduces the availability of properly processed substrates for Endoglycosidase H, thereby indirectly inhibiting its enzymatic action.

Celgosivir inhibits Endoglycosidase H by being an iminosugar derivative that can competitively inhibit glycosidases, including Endoglycosidase H, due to its structural similarity to monosaccharides. This competition at the active site prevents the cleavage of N-linked glycans.